期刊
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
卷 36, 期 9, 页码 2397-2407出版社
WILEY
DOI: 10.1111/jgh.15373
关键词
adalimumab; cost-effectiveness analysis; Crohn's disease; pediatrics; therapeutic drug monitoring
The study evaluated the cost-effectiveness of proactive versus reactive therapeutic drug monitoring of adalimumab in pediatric patients with Crohn's disease from the perspective of the US health-care provider. Results showed that proactive TDM led to higher quality-adjusted life-years at a lower cost compared to reactive TDM, with ADL drug cost being the most influential factor.
Background and Aim Recent clinical findings showed proactive therapeutic drug monitoring (TDM) of adalimumab (ADL) to improve sustained remission rate in pediatric patients with Crohn's disease (CD). The present study aimed to evaluate the potential cost-effectiveness of proactive versus reactive TDM of ADL in pediatric patients with CD from the perspective of the US health-care provider. Methods A Markov model was constructed to estimate outcomes of proactive versus reactive TDM of ADL in a hypothetical cohort of pediatric CD patients who were in remission on ADL maintenance treatment. Model inputs were derived from published literature and public data. Model outcomes included CD-related direct medical cost and quality-adjusted life-years (QALYs). Sensitivity analyses were performed to examine the robustness of base-case results. Results When compared with the reactive TDM group, the proactive TDM group saved 0.1960 QALYs at lower cost by USD2021 over a 3-year time frame in base-case analysis. One-way sensitivity analysis showed the ADL drug cost to be the most influential factor. Probabilistic sensitivity analysis of 10 000 Monte-Carlo simulations found the proactive TDM group to gain 0.1958 QALYs (95% confidence interval [CI] 0.1950-0.1966; P < 0.001) and save USD2037 (95%CI USD1943-2131; P < 0.001). Conclusions Proactive TDM for ADL seems to gain higher QALYs at lower cost in pediatric CD patients.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据